1. The involvement of intracellular 3': 5'-cyclic AMP in the inhibition of platelet aggregation by prostaglandin E1, isoprenaline and adenosine has been examined by a radiochemical technique. Platelet-rich plasma was incubated with radioactive adenine to incorporate 14C radioactivity into platelet nucleotides. Pairs of identically treated samples were taken, one for the photoinetric measurement of platelet aggregation induced by ADP, the other for estimation of the radioactivity of 3': 5'-cyclic AMP. 2. Theophylline, papaverine, dipyridamole and 2,6-bis-(diethanolamino)-4-piperidinopyrimido [5,4d] pyrimidine (compound RA233) were found to inhibit 3': 5'-cyclic AMP phosphodiesterase from platelets. At concentrations of 3': 5'-cyclic AMP greater than 50,uM the most active inhibitor was dipyridamole; at 3': 5'-cyclic AMP concentrations less than 19 PM, papaverine and compound RA233 were more active than dipyridamole. 3. In the presence of compound RA233 (50,UM), the effectiveness of prostaglandin E1 as an inhibitor of platelet aggregation was increased tenfold. Compound RA233 also increased the stimulation by prostaglandin E1 of the incorporation of radioactivity into 3': 5'-cyclic AMP. 4. Compound RA233 (50 pM) increased the effectiveness ofboth adenosine and 2-chloroadenosine as inhibitors of aggregation by 70-100-fold, and in the presence of compound RA233 both adenosine and 2-chloroadenosine stimulated the incorporation of radioactivity into 3': 5'-cyclic AMP; the extent of the stimulation was proportional to the logarithm of the nucleoside concentration. 5. Compound RA233 (100-500,UM) inhibited platelet aggregation by itself and caused small increases in the radioactivity of 3': 5'-cyclic AMP. Partial positive correlations were found between the radioactivity of 3': 5'-cyclic AMP in platelets measured at the time of addition of the aggregating agent (ADP) and the extent to which the aggregation was inhibited. 6. The results are interpreted as indicating that adenosine, 2-chloroadenosine, isoprenaline, prostaglandin E1 and drugs that inhibit platelet 3': 5'-cyclic AMP phosphodiesterase all inhibit aggregation by a common mechanism involving intracellular 3': 5'-cyclic AMP.
Human blood platelets in citrated platelet-rich plasma aggregate on the addition of ADP, and the effect of ADP is inhibited by the structurally similar compounds adenosine (Born, 1962; Born & Cross, 1963) , AMP (Born, 1962;  Packham, Ardlie & Mustard, 1969) and by 2-chloroadenosine (Born, 1964; Maguire & Michal, 1968) . The kinetics of this inhibition suggest a degree of competition between the inhibitors and ADP for a binding site at the platelet membrane (Skoza, Zucker, Jerushalmy & Grant, 1967; Maguire & Michal, 1968) , although this does not explain the fact that inhibition by adenosine and 2-chloroadenosine increases with time (Bom & Cross, 1963; Bom, 1964) . Also, AMP is less effective an inhibitor than adenosine, though more similar in structure to ADP. In human platelet-rich plasma the inhibitory effect of AMP can largely be attributed to breakdown to adenosine, and is greatly diminished by the addition of adenosine deaminase to the plasma (Rozenberg & Holmsen, 1968) .
Platelet aggregation is also inhibited by PGE1* (Kloeze, 1967; Emmons, Hampton, Harrison, Honour & Mitchell, 1967) which stimulates adenylate cyclase in particulate fractions of platelet homogenates (Wolfe & Shulman, 1969; Zieve & Greenough, 1969; Abdulla, 1969) . In the presence of theophylline, PGE1 increases platelet 3': 5'-cyclic AMP content * Abbreviation: PGEI, prostaglandin E1. 1D . C. B. MILLS AND J. B. SMITH (Robison, Arnold & Hartmann, 1969) and increases the radioactivity of 3': 5'-cyclic AMP in platelets with nucleotides labelled by the incorporation of radioactive adenosine or adenine (Mills, Smith & Born, 1970) . Inhibition of aggregation by both PGE1 and by isopropylnoradrenaline (isoprenaline) is potentiated by theophylline, an inhibitor of 3': 5'-cyclic AMP phosphodiesterase, at concentrations of theophylline that themselves do not inhibit (Mills et al. 1970 ). Ardlie, Glew & Schwartz (1967) found that higher concentrations of methylxanthines (theophylline and caffeine) inhibit aggregation and suggested that inhibition might involve 3': 5'-cyclic AMP. A variable increase in the concentration of 3': 5'-cyclic AMP in platelets treated with caffeine has been shown .
The drugs dipyridamole and papaverine, which block the incorporation of adenosine into platelets (Markwardt, Barthel, Glusa & Hoffman, 1967; Born & Mills, 1969; Mills et al. 1970 ) potentiate the inhibition of aggregation that adenosine causes. Adenosine and adenine nucleotides cause increases in 3': 5'-cyclic AMP in guinea-pig brain (Sattin & Rall, 1970) though subcellular preparations of adenylate cyclase from rat liver are inhibited by adenosine and by nucleotides (Moriwaki & Foa, 1970) . Dipyridamole and papaverine inhibit phosphodiesterase from ox heart (Poch, Juan & Kukovetz, 1969) and this suggests a possible alternative explanation for their action on platelets.
We have investigated the effects of papaverine and of dipyridamole and its analogues 2,6-bis(diethanolamino) -4 -piperidinopyrimido[5, 4d]-pyrimidine (compound RA233) and 2,4,6-trimorpholinopyrimido [5, 4d] pyrimidine (compound RA433) on platelet phosphodiesterase activity and on the inhibition of aggregation produced by PGE1 and by adenosine and 2-chloroadenosine-to determine the extent to which the formation of 3': 5'-cyclic AMP within the platelets is implicated in the inhibition of aggregation.
METHODS
Preparation of labelled platelet8. Citrated platelet-rich plasma was prepared from normal healthy donors by the method of Mills & Roberts (1967) and the platelets were labelled with [U-14C]adenine (sp. radioactivity 231mCi/ mmol) by the technique described by Ball, Fulwood, Ireland & Yates (1969). [U_14C]Adenine (1-1.5BM) was added to platelet-rich plasma and incubated for 45-80min. Samples were taken during this period and centrifuged to determine the extent of incorporation of 14C by counting the radioactivity of the supernatant plasma. A maximum of 85-90% of the added radioactivity was taken up and thereafter the plasma radioactivity increased by 5-10% of the total over the next 2 h. Platelet aggregation. Aggregation was studied photometrically (Born, 1962) as described in detail by Mills & Roberts (1967) , and measured as the maximum rate of change of optical transmission occurring 10-30s after addition of ADP. High concentrations of ADP (100-500y&M) were used because at low concentrations of ADP the kinetics of adenosine inhibition suggest competition with ADP (Skoza et al. 1967 ) whereas at higher concentrations this is not the case (Salzman, Ashford, Chambers, Neri & Dempster, 1969) . Preliminary experiments showed that when aggregation induced by 5,M-ADP was just completely suppressed by combinations of PGE, and theopbylline (Mills et al. 1970) expressed as a percentage of the total counts in the platelets in I.Oml of plasma. In one experiment, 14C-labelled platelets were isolated by adding EDTA (5mm) to plateletrich plasma, centrifuging at 2300g for 10 min at 4°C, and resuspending in 0.15 vol. of iso-osmotic saline (0.134 M-NaCl, 0.015M-tris-HCI buffer, pH7.4, 0.005M-glucose). Radioactivity of 3':5'-cyclic AMP was measured after isolation by paper chromatography (see Table 5 for details).
Preparation and assay of platelet 3':5'-cyclic AMP phosphodie8terase. Washed human platelets from 80ml of platelet-rich plasma were resuspended in 5ml of 0.154M-NaCl, sonicated twice for 10s (Dawe Soniprobe, model 1130A) and the homogenate was centrifuged at 17500g for 20min at 0C0. The supernatant, which contained essentially all the activity, was then dialysed overnight against 1 litre of 10mM-tris-HCl buffer, pH7.4, and the dialysed enzyme was stored at -15°C. Enzyme activity was retained on storage for at least 2 weeks, but was lost on successively thawing and refreezing. Phosphodiesterase activity was measured in 0.lOml incubation mixtures containing 5mM-MgSO4, 20mM-tris-HCI buffer, pH7. (Gornall, Bardawill & David, 1949 
RESULTS
Platelet pho8phodie8tera8e. The activity of a number of compounds as inhibitors of platelet 3': 5'-cyclic AMP phosphodiesterase was assessed at different concentrations of the 3': 5'-cyclic AMP substrate (Tables 1 and 2 ). Papaverine, dipyridamole and the dipyridamole analogues were tested at a final concentration in the incubation mixture of 50,uM; theophylline was tested at 1 mm (Table 1 ).
The order of activity of the inhibitors varied according to the concentration of substrate used. Dipyridamole, which was the most active of the inhibitors at a high 3': 5'-cyclic AMP concentration (130,UM) was less effective than papaverine, and compounds RA233 and RA433 at 3': 5'-cyclic AMP concentrations of 19 uM or less.
Adenosine, 5'-AMP and 2-chloroadenosine were also tested (Table 2 ). AMP at concentrations up to 3mM did not inhibit the enzyme; adenosine and 2-chloroadenosine caused partial inhibition at 0.3-3mM.
Platelet aggregation. In the experiment shown in Fig. 1 , isoprenaline, PGE1 and adenosine were tested as inhibitors of aggregation with and without the addition of compound RA233 (50tM, a con- Table 2 . Effects of adenosine, 2-chloroadeno8ine and Other details were as described for Table 1 -4.5 -10.6 300 2.0 11.7 -15.0 3000 27.1 57. 6 -13.4 centration that by itself had little effect on aggregation). Fig. 1 shows that there was a qualitatively similar synergism between compound RA233 and isoprenaline, PGE1 and adenosine. Concentrations of these compounds that by themselves had no effect on aggregation caused considerable inhibition in the presence of compound RA233. The shape of the aggregation curve in the presence of these combinations of inhibitors was different from the shape seen with various concentrations of ADP alone; for a given final change in transmission, the rate of change was lower in the inhibited samples than that brought about by low concentrations of ADP.
The radioactivity of 3': 5'-cyclic AMP was determined in samples of the same plasma prelabelled with radioactive adenine, by using the same drug concentrations and incubation times as were used Table 3 . Effect of inhibitors of platelet aggregation on the radioactivity of platelet 3': 5'-cyclic AMP Samples (1.Oml) of platelet-rich plasma, prelabelled with [14C]adenine, were incubated for 20s with or without compound RA233 (50ILM) before the addition of the second drug. Incubation was continued for a further 40s and the reaction was stopped by the addition of 50,1O of 11.4m-HC104 and transferring the tubes to an ice-bath. Samples for measurement of aggregation were treated in a similar manner, but the incubations were performed in the aggregometer and ADP (final concentration 500ILM) was added in place of HC104, and the rate of aggregation recorded (see Fig. 1 saline (see the Methods section), dipyridamole increased the effects of PGE1 on the radioactivity of 3': 5'-cyclic AMP measured 4min after the addition of PGE1. In this experiment 3': 5'-cyclic AMP was separated from other radioactive compounds by paper chromatography and higher control values were found than with the Dowex column procedure. For this reason, only increases in 3': 5'-cyclic AMP radioactivity are given. However, this procedure allowed a complete investigation of the distribution of radioactivity in the major fractions of platelet nucleotides as well as in 3': 5'-cyclic AMP. Neither compound RA233, theophylline nor PGEI, alone or in combination, Vol. 121 PGE, by itself, added 40s before ADP, caused inhibition of aggregation, with an S-shaped log (dose)-response curve at concentrationsof 0.02-1 KM (Fig. 2) . In the presence of compound RA233 (501%M) the dose-response curve was unaltered in shape but was shifted to the left to an extent equivalent to tenfold increase in the effectiveness of PGE1. Measurements of 3': 5'-cyclic AMP radioactivity made in the same experiment with labelled platelets are shown in Fig. 3 . PGE1 alone caused increases in the radioactivity of 3': 5'-cyclic AMP and in the presence of compound RA233 the increases were greater. However, compound RA233 caused a smaller potentiation of the effect of PGE1 on radioactive 3': 5'-cyclic AMP concentrations than on inhibition of aggregation. When the radioactivity of platelet 3': 5'-cyclic AMP was plotted against percentage inhibition of aggregation (Fig. 4) , three distinct curves were obtained, representing the effects of PGE1 alone, PGE1 together with compound RA233 (50tM) and high concentrations (100-250 tM) of compound RA233 alone. Under each of these conditions there was a relationship between the increase in radioactive 3': 5'-cyclic AMP measured at the time of addition of ADP and the inhibition of aggregation, but the relationship was different in each case. An increase PGE1 alone and by compound RA233 alone was associated with 10 and 60% inhibition of aggregation respectively. Adenofrne and 2-chloroadeno8ine. When added 40s before ADP, adenosine and 2-chloroadenosine inhibited aggregation to an extent that depended on concentration (Fig. 5) . Inhibition by 2-chloroadenosine increased linearly with the logarithm of the concentration and approached 100%; with adenosine inhibition increased up to 50% and then remained almost constant as the adenosine concentration was increased. In the presence of compound RA233 (50,UM) the dose-response curves were displaced to the left to an extent indicating about a 100-fold increase in effectiveness. In addition, the dose-response curve for adenosine in the presence of compound RA233 approached 100% inhibition.
Adenosine incubated for 40s with labelled platelets caused a small and variable increase in the that the observed increases were due to radioactive 3': 5'-cyclic AMP, extracts of labelled platelets were incubated with ox heart phosphodiesterase before the isolation procedure; of the radioactivity isolated as 3': 5'-cyclic AMP, 78% in the untreated platelets and 81 % in the stimulated platelets was susceptible to the action of phosphodiesterase (Table 6 ). Fig. 6 shows results from five experiments with blood from different donors in which increases in the radioactivity of platelet 3': 5'-cyclic AMP are plotted against adenosine concentration. The concentration of compound RA233 used in the different experiments was chosen to have little effect on aggregation but to potentiate the action of adenosine to about the same extent. A similar relationship between dose and increased 3': 5'-cyclic AMP radioactivity was found in three experiments with 2-chloroadenosine (Fig. 7) . Aggregation was measured in the same three experiments and Fig. 8 shows the relationship between increases in the radioactivity of platelet 3': 5'-cyclic AMP and percentage inhibition of aggregation. For a given increase in 3': 5'-cyclic AMP radioactivity there was a greater degree of inhibition of aggregation with the higher concentration of compound RA233. With combinations of adenosine and compound RA233 there was a general correlation between increases in 3': 5'-cyclic AMP radioactivity and inhibition of aggregation (r = 0.86, n = 11 in five experiments).
Comparisons between PGE1 and adenosine. The effects of theophylline and compound RA233 on inhibition of aggregation and on radioactive 3': 5'-cyclic AMP increases produced by PGE1 and by adenosine were compared in the experiment summarized in Table 7 . This shows that compound RA233 (20,UM) was less effective than theophylline other than inhibition of platelet phosphodiesterase is involvedinthe effects ofeithermethylxanthines or of the other compounds. The known abilities of papaverine and dipyridamole to inhibit the incorporation of adenosine by platelets, and the structural similarity between the RA compounds and dipyridamole, suggested the investigation ofthe effects of phosphodiesterase inhibitors on adenosine uptake. Inhibition of adeno8ine uptake. Dipyridamole, compound RA233 and theophylline were compared as iinhibitors of the uptake of radioactive adenosine by platelets (Table 8) . Dipyridamole inhibited adenosine uptake at low concentrations (0.5-51M) and compound RA233 also caused inhibition of uptake but at slightly higher concentrations; theophylline did not inhibit at up to 800 times the effective concentration of dipyridamole. Dipyridamole, the most active of the uptake inhibitors, did not cause any major potentiation of inhibition of aggregation produced by adenosine, nor was a combination of dipyridamole with theophylline more effective than theophylline alone. This indicates that the differences between these compounds as potentiators of adenosine and PGE, cannot be attributed to their effects on adenosine uptake. (1.5mM) in potentiating PGE1, but was more effective in combination with adenosine. In most experiments theophylline caused a slight inhibition of the adenosine effect. Both compound RA433 and papaverine behaved in a similar way to compound RA233. These differences suggest that some action 7 DISCUSSION A controlling function for intracellular 3': 5'-cyclic AMP on platelet aggregation has been put forward to explain the effects of drugs that inhibit 3': 5'-cyclic AMP phosphodiesterase (Ardlie et al. 1967 ) and of drugs that stimulate adenylate cyclase (Wolfe & Shulman, 1969; Zieve & Greenough, 1969; Marquis et al. 1969; Abdulla, 1969) . It has also been claimedthat there is an associationbetween the degree of inhibition of aggregation and the increased incorporation of radioactivity into 3': 5'-cyclic AMP in platelets containing radioactive ATP . In these latter experiments radioactive 3': 5'-cyclic AMP formation in the presence of 50mM-caffeine was compared with aggregation in the absence of caffeine. This concentration of caffeine strongly inhibits platelet aggregation by itself (Ardlie et al. 1967) .
We have attempted to correlate increases in radioactive 3': 5'-cyclicAMP formation with changes in platelet responsiveness to the aggregating effect of ADP under identical conditions. Such a correlation was observed with PGE1 over the concentration range 0.05-1,uM (Fig. 4) . The synergistic action of mixtures of PGE1 and theophylline on platelet aggregation (Mills et al. 1970) has been shown to be related to the co-operative effects of these drugs on the incorporation of radioactivity into platelet 3': 5'-cyclic AMP (Table 7) . This Bioch. 1971, 121 Vol. 121 193 g Table 7 . Potertiation of the effecte of PGE1 and adenosine on platelet aggregation and platelet 3': 5'-cyclic AMP radioactivity by pho8phodiemterame inhibitors Samples of platelet-rich plasma containing 5.30 x 108 platelets in 1 .Oml prelabelled with [14C] adenine were incubated at 370C in the aggregometer for lOs after addition of the phosphodiesterase inhibitor (first addition).
The second addition was then made and the incubation continued for a further 40s before transferring the contents of the aggregometer tube into a centrifuge tube containing 0.5ml of [3H]AMP as recovery standard. A l.0ml plastic syringe with a wide-bore needle with the bevel removed by grinding was used for the transfer. Aggregation was studied under identical conditions with samples of platelet-rich plasma preincubated with non-radioactive adenine. The basal 3':5'-cyclic AMP radioactivity was taken as the mean of three determinations made at the beginning, middle and end of the experiment (0.074, 0.064 and 0.085% as 3': 5'-cyclic AMP respectively).
First addition dependent increase in the degree of inhibition of aggregation that was correlated with increased accumulation of radioactive 3': 5'-cyclic AMP. This was also observed with increasing concentrations of compound RA233 alone. However, the slope of the correlation was different in the three cases (Fig. 4) , and the extent of the inhibition of aggregation associated with a given radioactive 3': 5'-cyclic AMP concentration was increased by the presence of compound RA233. This implies that the rate of aggregation is not directly related to the 3': 5'-cyclic AMP concentration measured at the time of addition of the aggregating agent. During aggregation induced by ADP there is a fall in the concentration and radioactivity (D. C. B. Mills & J. B. Smith, unpublished work) of platelet 3': 5'-cyclic AMP. If aggregation is controlled by the concentration of 3': 5'-cyclic AMP present during the course of, rather than immediately before, aggregation, an apparent increase in the effectiveness of 3': 5'-cyclic AMP by inhibitors of phosphodiesterase would be expected.
When low concentrations of ADP are used to induce aggregation, both dipyridamole and papaverine potentiate the inhibition of aggregation produced by adenosine and also block the incorporation of radioactive adenosine into the platelets (Bom & Mills, 1969) . This was interpreted as evidence that adenosine acts at the platelet membrane rather than during or after its penetration into the cells. Since the inhibition of aggregation by adenosine is, like that produced by PGE1 and by isoprenaline, potentiated by inhibitors of platelet 3': 5'-cyclic AMP phosphodiesterase, it could be explained as an activation of platelet membrane adenylate cyclase. Platelets incubated with adenosine and with 2-chloroadenosine showed small increases in radioactive 3': 5'-cyclic AMP formation over controls, but without any demonstrable dosedependence; this could be because the increases are transient, as they are with PGE, (Ball, Brereton, Fulwood, Ireland & Yates, 1970) . In the presence of the phosphodiesterase inhibitor compound RA233, the increases observed were larger and clearly correlated with the concentration of adenosine (Fig. 6 ) or 2-chloroadenosine ( Fig. 7) and with the degree of inhibition of aggregation produced (Fig. 8) .
If PGE1 and adenosine were acting solely through stimulation of adenylate cyclase, and theophylline and compound RA233 solely through inhibition of phosphodiesterase, then the relative extent of potentiation ofPGE1 and of adenosine by compound RA233 should match that produced by theophylline. Table 7 shows that compound RA233 was more active than theophylline as a potentiator of the effects of adenosine at concentrations that caused similar degrees of potentiation of PGE1. Compound RA233, but not theophylline, inhibited the uptake of adenosine by platelets (Table 8) . However, dipyridamole, an even more effective inhibitor of adenosine uptake than compound RA233, caused little or no potentiation of adenosine inhibition under these conditions (with aggregation induced by 1 00,uM-ADP) and a combination of dipyridamole with theophylline was no more effective than theophylline alone. This appears to rule out the possibility that the ability of compound RA233 to block the uptake of adenosine by platelets contributes to its activity as an adenosine potentiator. Theophylline antagonizes the effects of adenosine on 3': 5'-cyclic AMP concentration in guinea-pig cerebral-cortex slices (Sattin & Rall, 1970) . A similar effect in platelets would explain our results.
Adenosine and 2-chloroadenosine inhibit 3': 5'-cyclic AMP phosphodiesterase from ox heart (Horlington & Watson, 1970) . We found that 2-chloroadenosine and, to a lesser extent, adenosine, inhibited phosphodiesterase from human platelets, but only when present at relatively high concentrations ( Table 2 ). As adenosine is phosphorylated to nucleotides as rapidly as it is incorporated into platelets (Ireland & Mills, 1966) , it is unlikely that the concentration of adenosine available to interact with intracellular phosphodiesterase can reach the high concentrations that cause inhibition of the enzyme. Uptake and metabolism of 2-chloroadenosine by platelets have not been studied and inhibition of phosphodiesterase in intact cells by this compound cannot be excluded. The similarity in the effects of adenosine and 2-chloroadenosine suggest that this is not the case.
Assuming 3': 5'-cyclic AMP to be in equilibrium with the rapidly labelled fraction of platelet nucleotides (6,umol/1011 platelets; Mills & Thomas, 1969 ) the radioactivity of 3': 5'-cyclic AMP in untreated platelets corresponds to 3-7nmol/1011 platelets, increasing to 48nmol 40s after addition of 1 /uM-PGE1. This can be compared with the results of Robison et al. (1969) , who found a basal concentration of 2nmol/10'1 platelets, increasing to 14nmol 20min after addition of 1 ,aM-PGE1.
The similarities in the effects on platelet aggregation and on platelet 3': 5'-cyclic AMP radioactivity of low concentrations of PGE1 with those of adenosine and of 2-chloroadenosine suggest that these nucleosides inhibit aggregation by the same mechanism as does PGE1. The correlations obtained between increased radioactivity of 3': 5'-cyclic AMP and inhibition of aggregation indicate that this mechanism may involve the activation of platelet adenylate cyclase.
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